Frequent alteration of p63 expression in human primary bladder carcinomas

Bum Joon Park, Seung Jae Lee, Jin Il Kim, Sun Ju Lee, Choong Hyun Lee, Sung Goo Chang, Jae Hoon Park, Sung-Gil Chi

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

p63, a recently identified member of the p53 gene family, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. To explore the penetrance of p63 in bladder carcinogenesis, we performed expression and mutation analyses of two major isotypes, TAp63 and ΔNp63, in 63 bladder specimens. In 12 normal tissues, TAp63 was expressed at an easily detectable level whereas ΔNp63 was absent or extremely low. While none of 47 carcinomas showed allelic deletion of the gene, marked reduction of TAp63 and abnormal overexpresslon of ΔNp63 were found in 25 (53.2%) and 30 (63.8%) carcinomas, respectively. Tumor-specific alteration of TAp63 and ΔNp63 expression was identified in two and three of six matched sets, respectively. In addition, reduced expression of TAp63 showed a correlation with tumor stage and grade. Abnormal expression of TAp63 or ΔNp63 isoform was also observed in three of four cell lines, and treatment with 5-Aza-2'- deoxycytidine led to up- or down-regulation of TAp63 and/or ΔNp63 expression, suggesting that the promoters of both isoforms might be affected by DNA methylation, but not in a reciprocal fashion. No sequence alteration of p63 was identified in 47 carcinomas whereas 17 (34.8%) of these showed p53 mutations, and no association between p63 expression and the mutational status of p53 or expression of p2I(Waf1), MDM2, and 14-3.3σ was recognized. Our data suggest that altered expression of p63 is a frequent event in bladder carcinogenesis and might contribute to the progression of bladder tumors, possibly via the mechanism(s) distinct from the p53 pathway.

Original languageEnglish
Pages (from-to)3370-3374
Number of pages5
JournalCancer Research
Volume60
Issue number13
Publication statusPublished - 2000 Jul 1
Externally publishedYes

Fingerprint

Urinary Bladder
decitabine
Carcinoma
Protein Isoforms
Carcinogenesis
Mutation
Penetrance
p53 Genes
Gene Deletion
DNA Methylation
Urinary Bladder Neoplasms
Neoplasms
Up-Regulation
Down-Regulation
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Park, B. J., Lee, S. J., Kim, J. I., Lee, S. J., Lee, C. H., Chang, S. G., ... Chi, S-G. (2000). Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Research, 60(13), 3370-3374.

Frequent alteration of p63 expression in human primary bladder carcinomas. / Park, Bum Joon; Lee, Seung Jae; Kim, Jin Il; Lee, Sun Ju; Lee, Choong Hyun; Chang, Sung Goo; Park, Jae Hoon; Chi, Sung-Gil.

In: Cancer Research, Vol. 60, No. 13, 01.07.2000, p. 3370-3374.

Research output: Contribution to journalArticle

Park, BJ, Lee, SJ, Kim, JI, Lee, SJ, Lee, CH, Chang, SG, Park, JH & Chi, S-G 2000, 'Frequent alteration of p63 expression in human primary bladder carcinomas', Cancer Research, vol. 60, no. 13, pp. 3370-3374.
Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Research. 2000 Jul 1;60(13):3370-3374.
Park, Bum Joon ; Lee, Seung Jae ; Kim, Jin Il ; Lee, Sun Ju ; Lee, Choong Hyun ; Chang, Sung Goo ; Park, Jae Hoon ; Chi, Sung-Gil. / Frequent alteration of p63 expression in human primary bladder carcinomas. In: Cancer Research. 2000 ; Vol. 60, No. 13. pp. 3370-3374.
@article{63f8e5d6f19546c99cda401c0a57602e,
title = "Frequent alteration of p63 expression in human primary bladder carcinomas",
abstract = "p63, a recently identified member of the p53 gene family, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. To explore the penetrance of p63 in bladder carcinogenesis, we performed expression and mutation analyses of two major isotypes, TAp63 and ΔNp63, in 63 bladder specimens. In 12 normal tissues, TAp63 was expressed at an easily detectable level whereas ΔNp63 was absent or extremely low. While none of 47 carcinomas showed allelic deletion of the gene, marked reduction of TAp63 and abnormal overexpresslon of ΔNp63 were found in 25 (53.2{\%}) and 30 (63.8{\%}) carcinomas, respectively. Tumor-specific alteration of TAp63 and ΔNp63 expression was identified in two and three of six matched sets, respectively. In addition, reduced expression of TAp63 showed a correlation with tumor stage and grade. Abnormal expression of TAp63 or ΔNp63 isoform was also observed in three of four cell lines, and treatment with 5-Aza-2'- deoxycytidine led to up- or down-regulation of TAp63 and/or ΔNp63 expression, suggesting that the promoters of both isoforms might be affected by DNA methylation, but not in a reciprocal fashion. No sequence alteration of p63 was identified in 47 carcinomas whereas 17 (34.8{\%}) of these showed p53 mutations, and no association between p63 expression and the mutational status of p53 or expression of p2I(Waf1), MDM2, and 14-3.3σ was recognized. Our data suggest that altered expression of p63 is a frequent event in bladder carcinogenesis and might contribute to the progression of bladder tumors, possibly via the mechanism(s) distinct from the p53 pathway.",
author = "Park, {Bum Joon} and Lee, {Seung Jae} and Kim, {Jin Il} and Lee, {Sun Ju} and Lee, {Choong Hyun} and Chang, {Sung Goo} and Park, {Jae Hoon} and Sung-Gil Chi",
year = "2000",
month = "7",
day = "1",
language = "English",
volume = "60",
pages = "3370--3374",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Frequent alteration of p63 expression in human primary bladder carcinomas

AU - Park, Bum Joon

AU - Lee, Seung Jae

AU - Kim, Jin Il

AU - Lee, Sun Ju

AU - Lee, Choong Hyun

AU - Chang, Sung Goo

AU - Park, Jae Hoon

AU - Chi, Sung-Gil

PY - 2000/7/1

Y1 - 2000/7/1

N2 - p63, a recently identified member of the p53 gene family, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. To explore the penetrance of p63 in bladder carcinogenesis, we performed expression and mutation analyses of two major isotypes, TAp63 and ΔNp63, in 63 bladder specimens. In 12 normal tissues, TAp63 was expressed at an easily detectable level whereas ΔNp63 was absent or extremely low. While none of 47 carcinomas showed allelic deletion of the gene, marked reduction of TAp63 and abnormal overexpresslon of ΔNp63 were found in 25 (53.2%) and 30 (63.8%) carcinomas, respectively. Tumor-specific alteration of TAp63 and ΔNp63 expression was identified in two and three of six matched sets, respectively. In addition, reduced expression of TAp63 showed a correlation with tumor stage and grade. Abnormal expression of TAp63 or ΔNp63 isoform was also observed in three of four cell lines, and treatment with 5-Aza-2'- deoxycytidine led to up- or down-regulation of TAp63 and/or ΔNp63 expression, suggesting that the promoters of both isoforms might be affected by DNA methylation, but not in a reciprocal fashion. No sequence alteration of p63 was identified in 47 carcinomas whereas 17 (34.8%) of these showed p53 mutations, and no association between p63 expression and the mutational status of p53 or expression of p2I(Waf1), MDM2, and 14-3.3σ was recognized. Our data suggest that altered expression of p63 is a frequent event in bladder carcinogenesis and might contribute to the progression of bladder tumors, possibly via the mechanism(s) distinct from the p53 pathway.

AB - p63, a recently identified member of the p53 gene family, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. To explore the penetrance of p63 in bladder carcinogenesis, we performed expression and mutation analyses of two major isotypes, TAp63 and ΔNp63, in 63 bladder specimens. In 12 normal tissues, TAp63 was expressed at an easily detectable level whereas ΔNp63 was absent or extremely low. While none of 47 carcinomas showed allelic deletion of the gene, marked reduction of TAp63 and abnormal overexpresslon of ΔNp63 were found in 25 (53.2%) and 30 (63.8%) carcinomas, respectively. Tumor-specific alteration of TAp63 and ΔNp63 expression was identified in two and three of six matched sets, respectively. In addition, reduced expression of TAp63 showed a correlation with tumor stage and grade. Abnormal expression of TAp63 or ΔNp63 isoform was also observed in three of four cell lines, and treatment with 5-Aza-2'- deoxycytidine led to up- or down-regulation of TAp63 and/or ΔNp63 expression, suggesting that the promoters of both isoforms might be affected by DNA methylation, but not in a reciprocal fashion. No sequence alteration of p63 was identified in 47 carcinomas whereas 17 (34.8%) of these showed p53 mutations, and no association between p63 expression and the mutational status of p53 or expression of p2I(Waf1), MDM2, and 14-3.3σ was recognized. Our data suggest that altered expression of p63 is a frequent event in bladder carcinogenesis and might contribute to the progression of bladder tumors, possibly via the mechanism(s) distinct from the p53 pathway.

UR - http://www.scopus.com/inward/record.url?scp=0034234312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234312&partnerID=8YFLogxK

M3 - Article

C2 - 10910040

AN - SCOPUS:0034234312

VL - 60

SP - 3370

EP - 3374

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -